New Breast Cancer Patient Resource Is Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 11
Volume 5
Issue 11

WILMINGTON, Del-The Breast Cancer Patient Education Service, recently established by Zeneca Pharmaceuticals, allows breast cancer patients and their families to obtain patient education materials on tamoxifen (Nolvadex) with one phone call.

WILMINGTON, Del—The Breast Cancer Patient Education Service, recently established by Zeneca Pharmaceuticals, allows breast cancer patients and their families to obtain patient education materials on tamoxifen (Nolvadex) with one phone call.

The service provides the Progress for Life educational package, which includes written materials explaining breast cancer issues in easy-to-understand language and a video featuring experts on tamoxifen treatment, as well as useful toll-free numbers for other breast cancer information resources.

Patients can access the service by calling 1-800-34-LIFE-4 (1-800-345-4334), Monday through Friday, 8:15 AM until 4:30 PM Eastern Standard Time.

Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content